Amplia Therapeutics Limited, a clinical-stage drug development company, engages in the development of focal adhesion kinase (FAK) inhibitors for cancer and fibrosis in Australia. Its product pipeline comprises Narmafotinib (AMP945), an inhibitor of FAK, which is in 1b/2a clinical trial for pancreatic cancer; and treatment of idiopathic pulmonary fibrosis, as well as ovarian cancer. It also develops AMP886 for application in oncology and chronic fibrosis indications. The company was formerly know...
Industry: Biotechnology
Sector: Healthcare
Phone: 61 3 9123 1140
Fax: 61 3 9473 2555
Address:
350 Queen Street, Level 17, Melbourne, Australia
